As noted in diabetes management guidelines, SGLT2 inhibitors are generally avoided or used with caution in high‐risk patients (e.g., those with recurrent UTIs or underlying urologic disorders) [50]; therefore, they tend to be prescribed to transplant recipients with relatively low baseline infection risk. The gene discussed is SLC5A2; the disease is urinary system disorder.